Open AccessExtended cancer-free survival after palliative chemoradiation for metastatic esophageal cancer
Author(s) -
Hideomi Yamashita,
Kae Okuma,
Akihiro Nomoto,
Mami Yamashita,
Hiroshi Igaki,
Keiichi Nakagawa
Publication year - 2014
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v6.i2.52
Subject(s) - medicine , nedaplatin , esophagitis , radiation therapy , cancer , esophageal cancer , chemotherapy , palliative care , stage (stratigraphy) , carcinoma , oncology , toxicity , nuclear medicine , radiology , cisplatin , disease , paleontology , nursing , reflux , biology
We report on a patient who remained cancer-free for an extended time after palliative radiotherapy (RT) and chemotherapy (nedaplatin plus 5-fluorouracil) treatment for stage IV (cT3N3M1) esophageal squamous cell carcinoma. Although multiple lymph nodes outside the RT field recurred, the local primary tumor within the RT field did not recur, even 17 mo after palliative RT of 30 Gy in 10 fractions. In this case, acute toxicity, such as myelosuppression or esophagitis, was not enhanced by increasing the fraction dose from 1.8-2.0 Gy to 3.0 Gy. Because 30 Gy in 10 fractions can be completed within a shorter time and is less expensive than 50.4 Gy in 28 fractions, we think that 30 Gy without oblique beams is a more favorable RT method for patients.